{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:21:32Z","timestamp":1760908892650},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,4,30]],"date-time":"2014-04-30T00:00:00Z","timestamp":1398816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s00277-014-2077-1","type":"journal-article","created":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T07:17:00Z","timestamp":1398755820000},"page":"1551-1558","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience"],"prefix":"10.1007","volume":"93","author":[{"given":"A.","family":"Garc\u00eda-Noblejas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mart\u00ednez Chamorro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Navarro Matilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Da Silva Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. J.","family":"Gonz\u00e1lez-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"O\u00f1a Navarrete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Ram\u00edrez S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Mart\u00ednez Barranco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"S\u00e1nchez Blanco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Nicol\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"S\u00e1nchez Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Ruedas L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Domingo-Domenech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Panizo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Macia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Fern\u00e1ndez-Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Cannata-Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Arranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,4,30]]},"reference":[{"key":"2077_CR1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris N, Jaffe E, Pileri S, Stein H et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC Press, Lyon, France","edition":"4"},{"issue":"5","key":"2077_CR2","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","volume":"20","author":"OM Howard","year":"2002","unstructured":"Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ et al (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20(5):1288\u20131294","journal-title":"J Clin Oncol"},{"issue":"9","key":"2077_CR3","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, W\u00f6rmann B, D\u00fchrsen U, Metzner B et al (2005) Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23(9):1984\u20131992","journal-title":"J Clin Oncol"},{"issue":"4","key":"2077_CR4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","volume":"16","author":"F Lefr\u00e8re","year":"2002","unstructured":"Lefr\u00e8re F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M et al (2002) Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 16(4):587\u2013593","journal-title":"Leukemia"},{"issue":"28","key":"2077_CR5","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"JE Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B et al (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23(28):7013\u20137023","journal-title":"J Clin Oncol"},{"issue":"7","key":"2077_CR6","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112(7):2687\u20132693","journal-title":"Blood"},{"key":"2077_CR7","doi-asserted-by":"crossref","unstructured":"Hermine O, Hoster E, Walewski J, Ribrag V, Brousse N, Thieblemont C et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP Plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). American Society of Hematology Annual Meeting. 2012. [Abstract] Dec 120; Atlanta: 151","DOI":"10.1182\/blood.V120.21.151.151"},{"issue":"3","key":"2077_CR8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","volume":"6","author":"E Zucca","year":"1995","unstructured":"Zucca E, Roggero E, Pinotti G, Pedrinis E, Capella C, Venco A et al (1995) Patterns of survival in mantle cell lymphoma. Ann Oncol 6(3):257\u2013262","journal-title":"Ann Oncol"},{"issue":"5","key":"2077_CR9","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","volume":"120","author":"E Vandenberghe","year":"2003","unstructured":"Vandenberghe E, Ruiz de Elvira C, Loberiza FR et al (2003) Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 120(5):793\u2013800","journal-title":"Br J Haematol"},{"key":"2077_CR10","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","volume":"21","author":"IF Khouri","year":"2003","unstructured":"Khouri IF, Lee MS, Saliba RM et al (2003) Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma. J Clin Oncol 21:4407\u20134412","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2077_CR11","first-page":"236 (a)","volume":"37","author":"Robinson","year":"2006","unstructured":"Robinson et al (2006) Reduced-intensity conditioning and allogenic stem cell transplantation in mantle cell lymphoma: an update from the Lymphoid Working Party of the EBMT. Bone Marrow Transplant 37(Suppl 1):236 (a)","journal-title":"Bone Marrow Transplant"},{"issue":"18","key":"2077_CR12","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1182\/blood-2008-10-184200","volume":"113","author":"CS Tam","year":"2009","unstructured":"Tam CS, Bassett R, Ledesma C et al (2009) Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113(18):4144\u20134152","journal-title":"Blood"},{"issue":"Suppl 1","key":"2077_CR13","first-page":"753 (a)","volume":"43","author":"J Gayoso","year":"2009","unstructured":"Gayoso J, Martino R, Balsalobre P et al (2009) (GELTAMO). Long-term results of fludarabine\/melphalan as reduced-intensity conditioning regimen in mantle cell lymphoma: age matters. Bone Marrow Transplant 43(Suppl 1):753 (a)","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"2077_CR14","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J et al (2009) Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27(23):3822\u20133829","journal-title":"J Clin Oncol"},{"issue":"30","key":"2077_CR15","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS et al (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24(30):4867\u20134874","journal-title":"J Clin Oncol"},{"issue":"7","key":"2077_CR16","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","volume":"22","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Vose JM, Zinzani PL et al (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma. Ann Oncol 22(7):1622\u20131627","journal-title":"Ann Oncol"},{"issue":"7","key":"2077_CR17","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2011.041392","volume":"96","author":"W Lamm","year":"2011","unstructured":"Lamm W, Kaufmann H, Raderer M, Hoffmann M, Chott A, Zielinski C, Drach J (2011) Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 96(7):1008\u20131014","journal-title":"Haematologica"},{"issue":"4","key":"2077_CR18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","volume":"12","author":"SM Ansell","year":"2011","unstructured":"Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K et al (2011) Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 12(4):361\u2013368","journal-title":"Lancet Oncol"},{"issue":"7","key":"2077_CR19","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","volume":"13","author":"M Wang","year":"2012","unstructured":"Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS et al (2012) Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial. Lancet Oncol 13(7):716\u2013723","journal-title":"Lancet Oncol"},{"issue":"15","key":"2077_CR20","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D et al (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol 23(15):3383\u20133389","journal-title":"J Clin Oncol"},{"issue":"27","key":"2077_CR21","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A et al (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 26(27):4473\u20134479","journal-title":"J Clin Oncol"},{"issue":"4","key":"2077_CR22","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244","journal-title":"J Clin Oncol"},{"issue":"36","key":"2077_CR23","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","volume":"27","author":"LE Damon","year":"2009","unstructured":"Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL et al (2009) Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 27(36):6101\u20136108","journal-title":"J Clin Oncol"},{"issue":"3","key":"2077_CR24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","volume":"156","author":"F Merli","year":"2012","unstructured":"Merli F, Luminari S, Ilariucci F, Petrini M, Visco C, Ambrosetti A et al (2012) Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 156(3):346\u2013353","journal-title":"Br J Haematol"},{"issue":"3","key":"2077_CR25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","volume":"158","author":"CH Geisler","year":"2012","unstructured":"Geisler CH, Kolstad A, Laurell A, Jerkeman M, R\u00e4ty R, Andersen NS et al (2012) Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 158(3):355\u2013362","journal-title":"Br J Haematol"},{"issue":"2","key":"2077_CR26","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","volume":"102","author":"AM Gianni","year":"2003","unstructured":"Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S et al (2003) Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102(2):749\u2013755","journal-title":"Blood"},{"issue":"1","key":"2077_CR27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","volume":"14","author":"LM Leoni","year":"2008","unstructured":"Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J et al (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14(1):309\u2013317","journal-title":"Clin Cancer Res"},{"key":"2077_CR28","doi-asserted-by":"crossref","first-page":"1632 (a)","DOI":"10.1182\/blood.V120.21.1632.1632","volume":"120","author":"MS Czuczman","year":"2012","unstructured":"Czuczman MS, Lamonica D, Gaylor SK, Bush, Nadolny P et al (2012) Open-Label bendamustine Combined with rituximab for treatment of relapsed\/refractory mantle-cell lymphoma: efficacy and safety findings. Blood 120:1632 (a)","journal-title":"Blood"},{"issue":"9873","key":"2077_CR29","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203\u20131210","journal-title":"Lancet"},{"issue":"11","key":"2077_CR30","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1080\/10428190701618268","volume":"48","author":"J Rodr\u00edguez","year":"2007","unstructured":"Rodr\u00edguez J, Gutierrez A, Palacios A, Navarrete M, Blancas I, Alarc\u00f3n J et al (2007) Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma 48(11):2172\u20132178","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2077_CR31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00277-012-1422-5","volume":"91","author":"L Rigacci","year":"2012","unstructured":"Rigacci L, Puccini B, Cortelazzo S, Gaidano G, Piccin A, D\u2019Arco A et al (2012) Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin\u2019s lymphoma patients: a multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). Ann Hematol 91(7):1013\u20131022","journal-title":"Ann Hematol"},{"issue":"6","key":"2077_CR32","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.leukres.2011.10.024","volume":"36","author":"B Sanchez-Gonzalez","year":"2012","unstructured":"Sanchez-Gonzalez B, Pe\u00f1alver FJ, Medina A, Guill\u00e9n H, Calleja M, Gironella M et al (2012) Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain. Leuk Res 36(6):709\u2013714","journal-title":"Leuk Res"},{"issue":"7","key":"2077_CR33","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3109\/10428194.2011.649476","volume":"53","author":"S Warsch","year":"2012","unstructured":"Warsch S, Hosein PJ, Maeda LS, Alizadeh AA, Lossos IS (2012) A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. Leuk Lymphoma 53(7):1299\u20131305","journal-title":"Leuk Lymphoma"},{"key":"2077_CR34","doi-asserted-by":"crossref","first-page":"856 (a)","DOI":"10.1182\/blood.V116.21.856.856","volume":"116","author":"MJ Rummel","year":"2010","unstructured":"Rummel MJ, Kaiser U, Balser C, Stauch MB, Brugger W, Welslau M et al (2010) Bendamustine plus rituximab versus fludarabine plus rituximab in patients with relapsed follicular, indolent and mantle cell lymphomas: final results of the randomized phase III study NHL 2\u20132003 on behalf of the StiL (Study Group Indolent Lymphomas, Germany). Blood 116:856 (a)","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2077-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-014-2077-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-014-2077-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T14:04:26Z","timestamp":1597759466000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-014-2077-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,30]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["2077"],"URL":"https:\/\/doi.org\/10.1007\/s00277-014-2077-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,30]]}}}